drugset
drugset / Trial / NCT06715891

Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years

NCT06715891 ↗

Phase 3 Recruiting 374 enrolled Materia Medica Holding
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial.

Timeline

Start
2024-11-11
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Raphamin Unknown 1 unknown Oral

Indications

viral respiratory tract infection